Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complications associated with barbiturate therapy.

M Sato1, S Tanaka, K Suzuki

  • 1Department of Neurosurgery, Kinki University School of Medicine, Osaka, Japan.

Resuscitation
|June 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social implementation of early psychiatric intervention and youth mental health services in Japan.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan·2025
Same author

DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway.

Molecular psychiatry·2017
Same author

NFκB2 Gene as a Novel Candidate that Epigenetically Responds to Interval Walking Training.

International journal of sports medicine·2015
Same author

Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.

Oncogene·2010
Same author

[Diffusion-weighted imaging of brain death: study of apparent diffusion coefficient].

No to shinkei = Brain and nerve·2002
Same author

An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2.

Biochemical and biophysical research communications·2001

High-dose barbiturate therapy for elevated intracranial pressure led to more complications, including infections and organ damage, compared to low-dose or no therapy. These complications, particularly pneumonia, increased patient mortality in the high-dose group.

Area of Science:

  • Neurology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Elevated intracranial pressure (ICP) is a critical condition often resulting from cerebrovascular accidents or head injuries.
  • Barbiturate therapy is a potential treatment for managing elevated ICP.

Purpose of the Study:

  • To evaluate the complications associated with different doses of barbiturate therapy in patients with elevated intracranial pressure.
  • To compare the incidence of adverse events between low-dose, high-dose barbiturate therapy, and a control group.

Main Methods:

  • A study involving 56 patients with elevated ICP, divided into low-dose barbiturate (n=15), high-dose barbiturate (n=24), and control (n=17) groups.
  • Thiamylal was used for barbiturate therapy, and all complications were meticulously recorded.

Related Experiment Videos

  • Patient outcomes, including organ-specific complications and mortality, were analyzed.

    • Main Results:

    • Pulmonary, renal, and hepatic complications were more frequent in barbiturate-treated groups, especially the high-dose group, compared to controls.
    • Opportunistic infections, notably pneumonia, occurred in 10 patients receiving barbiturates versus 1 in the control group.
    • Three deaths were linked to barbiturate-related complications, contrasting with one death in the control group not associated with therapy.

    Conclusions:

    • High-dose barbiturate therapy for elevated intracranial pressure is associated with a significantly higher risk of severe complications, including organ damage and opportunistic infections.
    • The increased complication rate, particularly pneumonia, in the high-dose group may contribute to increased mortality.
    • Careful consideration of risk-benefit is warranted when administering barbiturates for elevated ICP.